FTY720: Early clinical experience

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S544-S548

  Dragun, D ^a   Fritsche, L ^a   Boehler, T ^a   Peters, H ^a   Budde, K ^a   Neumayer, H H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FINGOLIMOD; IMMUNOMODULATING AGENT; RAPAMYCIN; TACROLIMUS;

ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BRADYCARDIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TITRIMETRY;

EID: 1642377169     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.12.048     Document Type: Article

References (27)

1. Tejani A., Stablein D.M., Donaldson L., et al. Terasaki P.I., Cecka J.M. Clinical Transplants 1999. 1999;95 UCLA Tissue Typing Laboratory, Los Angeles, Calif.
2. Nair R.V., Morris R.E. Immunosuppression in cardiac transplantation a new era in immunopharmacology. Curr Opin Cardiol. 10:1995;207.
3. Brinkmann V., Lynch K. FTY720 targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 14:2002;569.
4. Aki T.F., Kahan B.D. FTY720 a new kid on the block for transplant immunosuppression. Expert Opin Biol Ther. 3:2003;665.
5. Brinkmann V., Davies M.D., Heise C.E., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 277:2002;21453.
6. Mandala S., Hajdu R., Bergstrom J., et al. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science. 296:2002;346.
7. Chiba K., Yanagawa Y., Masubuchi Y., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 160:1998;5037.
8. Pinschewer D.D., Ochsenbein A.F., Odermatt B., et al. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 164:2000;5761.
9. Yanagawa Y., Sugahara K., Kataoka H., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats II. FTY720 prolongs skin allograft survival by decreasing T-cell infiltration into grafts but not cytokine production in vivo. J Immunol. 160:1998;5493.
10. Hoshino Y., Suzuki S., Kobayashi E., et al. FTY720, a novel immunosuppressant possessing unique mechanisms: II. Long-term graft survival induction in rat heterotropic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc. 28:1996;1060.
11. Suzuki T., Shimamura T., Jin M.B., et al. Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. Transplant Proc. 31:1999;1208.
12. Furukawa H., Suzuki T., Jin M.B., et al. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720. Transplantation. 69:2000;235.
13. Brinkmann V., Chen S., Feng L., et al. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc. 33:2001;530.
14. Brinkmann V., Pinschewer D.D., Feng L., et al. FTY720 altered lymphocyte traffic results in allograft protection. Transplantation. 72:2001;764.
15. Stepkowski S.M., Wang M., Qu X., et al. Synergistic interaction of FTY720 with cyclosporin or sirolimus to prolong heart allograft survival. Transplant Proc. 30:1998;2214.
16. Nikolova Z., Hof A., Baumlin Y., et al. The peripheral lymphocyte count predicts graft in DA to Lewis heterotropic heart transplantation treated with FTY720 and SDZ RAD. Transplant Immunol. 8:2000;115.
17. Tamura A., Li X.K., Funeshima N., et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. Transplant Proc. 31:1999;2785.
18. Nikolova Z., Hof A., Rudin M., et al. Prevention of graft vessel disease by combined FTY720 and cyclosporin A treatment in the DA to Lewis rat carotid artery transplantation model. Transplantation. 69:2000;2525.
19. Budde K., Schmouder R.L., Brunkhorst R., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 13:2002;1073.
20. Budde K., Schmouder R.L., Nashan B., et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant. 3:2003;846.
21. Kahan BD, Karlix JL, Ferguson RM, et al: Pharmacodynamics, pharmacokinetics and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter randomized, placebo-controlled, phase I study. Transplantation 76:1079, 2003.
22. Quesniaux V., Fullard L., Arendse H., et al. A novel immunosuppressant. FTY720 induces peripheral lymphodepletion of both T- and B-cells and immunosuppression in baboons. Transpl Immunol. 7:1999;149.
23. Troncoso P., Kahan B.D. Preclinical evaluation of a new immunosuppressive agent, FTY720. Clin Biochem. 31:1998;369.
24. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 331:1994;1110.
25. de Mattos A.M., Olyaei A.J., Bennett W.M. Nephrotoxicity of immunosuppressive drugs long-term consequences and challenges for the future. Am J Kidney Dis. 35:2000;333.
26. Mazurais D., Robert P., Gout B., et al. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 50:2002;661.
27. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch 438:642, 1999.